News

Oct 20, 2023 at 11:00 AM Eastern / 08:00 AM Pacific Join us as we discuss the latest research and best practices in preventing complications associated with retained blood, equipping you with valuable insights to enhance patient care and safety. Industry experts will discuss evidence-based strategies that can make a significant impact in healthcare settings. The Importance and Benefits of Maintenance of Chest Tube Patency to Prevent Retained…

Reduction in chest tube clogging and take back for bleeding shown in randomized prospective clinical trial with PleuraFlow ACT System IRVINE, CA —March 30, 2021 ClearFlow, Inc., a medical device company based in Irvine, California, has announced positive clinical trial results published in the peer-reviewed Journal of Cardiothoracic Surgery. The findings are reported by cardiac surgeons at the Montreal Heart Institute, in Montreal, Quebec, Canada in the article,…

Reduction of Patient Complications After Heart Surgery Demonstrated with Use of the ClearFlow’s PleuraFlow ACT System Irvine, CA – October 20, 2020  — ClearFlow, Inc., a medical device company based in Irvine, California, has announced positive clinical trial results presented at the 2020 Virtual Program of the Annual Eastern Cardiothoracic Surgical Society Conference (ECTSS) on October 8th.  The trial evaluated the use of the ClearFlow’s PleuraFlow® Active Clearance Technology® (ACT®) System in…

Reduction of Patient Complications and Hospital Resource Utilization After Heart Surgery Demonstrated with Use of the PleuraFlow ACT System   Irvine, CA – November 20, 2019 — ClearFlow, Inc., a medical device company based in Irvine, California, has announced positive clinical trial results published in the peer-reviewed Journal of Cardiothoracic Surgery.  The trial evaluated the use of the PleuraFlow® Active Clearance Technology® (ACT®) System in prevention of retained blood complications in heart surgery…

Anaheim, California–May 7, 2019–ClearFlow, Inc., a medical device company based in Anaheim, California, has announced that positive clinical trial results of its PleuraFlow® device were presented at the American Association for Thoracic Surgery (AATS) 99th Annual meeting on May 4 in Toronto, Canada.  This new data stems from a trial evaluating the use of ClearFlow’s PleuraFlow® Active Clearance Technology® (ACT®) System in heart surgery patients at the Montreal…

ERAS Cardiac Surgery Featured at Dedicated Session at European Association for Cardio-Thoracic Surgery in Milan   Springfield, MA — October 24, 2018 — The ERAS Cardiac Surgery Society presented its recent consensus statement at the 32nd European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting in Milan, Italy, last week as part of an educational session.   This dedicated ERAS Cardiac Surgery session was held during EACTS, the world’s largest…

Anaheim, CA – August 21, 2018— ClearFlow, Inc., a medical device company based in Anaheim, California, announced today that it has been awarded a group purchasing agreement for the Chest Drainage Products category with Premier.   Effective July 15th 2018, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for:   PleuraFlow Active Clearance Technology (ACT) System;…

Boston, MA – May 29th, 2018 — ClearFlow, Inc., a medical device company based in Anaheim, California, has announced that positive clinical trial results were presented at the National Teaching Institute (NTI) & Critical Care Exposition 2018 annual meeting on May 23rd, 2018 in Boston, MA. The findings were presented by the study principal investigator, Dr. Yvon Baribeau, of Catholic Medical Center in Manchester, New Hampshire, in a…